Tags

Type your tag names separated by a space and hit enter

Omega-3 fatty acids and cardiovascular disease.
Curr Opin Clin Nutr Metab Care 2007; 10(2):129-35CO

Abstract

PURPOSE OF REVIEW

In the last 2 years in the cardiovascular field eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been investigated in terms of their epidemiology and vascular biology, and in large-scale intervention trials, and incorporated into the guidelines of cardiac societies. EPA and DHA have advanced from scientific research into everyday practice, a development reviewed here.

RECENT FINDINGS

EPA and DHA are antiarrhythmic on the supraventricular and ventricular levels, besides having an anti-atherosclerotic effect. Fish rich in EPA and DHA, contaminated with methyl-mercury, appears less protective. Large-scale clinical trials demonstrated that morbidity can be reduced with EPA even in a population already consuming large amounts of EPA and DHA. Therapy with EPA and DHA can be monitored with the omega-3 index, a risk factor for sudden cardiac death. EPA and DHA appear to be cost-saving in the USA, and, as Omacor, are cost-effective in several European countries.

SUMMARY

European and American Cardiac Societies incorporated EPA and DHA into recent treatment guidelines for myocardial infarction, prevention of cardiovascular disease, treatment of ventricular arrhythmias and prevention of sudden cardiac death. Physicians need to reduce the burden of cardiovascular disease by advocating EPA and DHA to all patients likely to benefit.

Authors+Show Affiliations

Preventive Cardiology, Medizinische Klinik und Poliklinik Innenstadt, Ludwig Maximilians-Universität München, Münich, Germany. Clemens.vonschacky@med.uni-muenchen.de

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17284999

Citation

von Schacky, Clemens. "Omega-3 Fatty Acids and Cardiovascular Disease." Current Opinion in Clinical Nutrition and Metabolic Care, vol. 10, no. 2, 2007, pp. 129-35.
von Schacky C. Omega-3 fatty acids and cardiovascular disease. Curr Opin Clin Nutr Metab Care. 2007;10(2):129-35.
von Schacky, C. (2007). Omega-3 fatty acids and cardiovascular disease. Current Opinion in Clinical Nutrition and Metabolic Care, 10(2), pp. 129-35.
von Schacky C. Omega-3 Fatty Acids and Cardiovascular Disease. Curr Opin Clin Nutr Metab Care. 2007;10(2):129-35. PubMed PMID: 17284999.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Omega-3 fatty acids and cardiovascular disease. A1 - von Schacky,Clemens, PY - 2007/2/8/pubmed PY - 2007/5/1/medline PY - 2007/2/8/entrez SP - 129 EP - 35 JF - Current opinion in clinical nutrition and metabolic care JO - Curr Opin Clin Nutr Metab Care VL - 10 IS - 2 N2 - PURPOSE OF REVIEW: In the last 2 years in the cardiovascular field eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been investigated in terms of their epidemiology and vascular biology, and in large-scale intervention trials, and incorporated into the guidelines of cardiac societies. EPA and DHA have advanced from scientific research into everyday practice, a development reviewed here. RECENT FINDINGS: EPA and DHA are antiarrhythmic on the supraventricular and ventricular levels, besides having an anti-atherosclerotic effect. Fish rich in EPA and DHA, contaminated with methyl-mercury, appears less protective. Large-scale clinical trials demonstrated that morbidity can be reduced with EPA even in a population already consuming large amounts of EPA and DHA. Therapy with EPA and DHA can be monitored with the omega-3 index, a risk factor for sudden cardiac death. EPA and DHA appear to be cost-saving in the USA, and, as Omacor, are cost-effective in several European countries. SUMMARY: European and American Cardiac Societies incorporated EPA and DHA into recent treatment guidelines for myocardial infarction, prevention of cardiovascular disease, treatment of ventricular arrhythmias and prevention of sudden cardiac death. Physicians need to reduce the burden of cardiovascular disease by advocating EPA and DHA to all patients likely to benefit. SN - 1363-1950 UR - https://www.unboundmedicine.com/medline/citation/17284999/Omega_3_fatty_acids_and_cardiovascular_disease_ L2 - http://Insights.ovid.com/pubmed?pmid=17284999 DB - PRIME DP - Unbound Medicine ER -